The State of the Art of Theranostic Nanomaterials for Lung, Breast, and Prostate Cancers

• Published in: Nanomaterials (Basel, Switzerland) Vol. 11; no. 10; p. 2579
• Main Authors: Freitas, Lucas F, Ferreira, Aryel H, Thipe, Velaphi C, Varca, Gustavo H C, Lima, Caroline S A, Batista, Jorge G S, Riello, Fabiane N, Nogueira, Kamila, Cruz, Cassia P C, Mendes, Giovanna O A, Rodrigues, Adriana S, Sousa, Thayna S, Alves, Victoria M, Lugão, Ademar B
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30-09-2021; MDPI
• Subjects: Biocompatibility; Blood vessels; Breast cancer; Clinical trials; Cytotoxicity; Dendrimers; Drug delivery; Efficiency; Ethnicity; Immune response; Lung cancer; Lungs; Medical imaging; Medical prognosis; Nanomaterials; Nanoparticles; Nanotechnology; Polymers; Prostate cancer; Quantum dots; Review; State-of-the-art reviews; theranostics; Tumors; lung cancer; nanotechnology; breast cancer; theranostics; prostate cancer; nanomaterials
• ISSN: 2079-4991; 2079-4991
• DOI: 10.3390/nano11102579

The synthesis and engineering of nanomaterials offer more robust systems for the treatment of cancer, with technologies that combine therapy with imaging diagnostic tools in the so-called nanotheranostics. Among the most studied systems, there are quantum dots, liposomes, polymeric nanoparticles, inorganic nanoparticles, magnetic nanoparticles, dendrimers, and gold nanoparticles. Most of the advantages of nanomaterials over the classic anticancer therapies come from their optimal size, which prevents the elimination by the kidneys and enhances their permeation in the tumor due to the abnormal blood vessels present in cancer tissues. Furthermore, the drug delivery and the contrast efficiency for imaging are enhanced, especially due to the increased surface area and the selective accumulation in the desired tissues. This property leads to the reduced drug dose necessary to exert the desired effect and for a longer action within the tumor. Finally, they are made so that there is no degradation into toxic byproducts and have a lower immune response triggering. In this article, we intend to review and discuss the state-of-the-art regarding the use of nanomaterials as therapeutic and diagnostic tools for lung, breast, and prostate cancer, as they are among the most prevalent worldwide.